Sonoma Pharmaceuticals (O8Z) AI Stock Analysis

Top Page

Sonoma Pharmaceuticals

(Frankfurt:O8Z)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Revenue Growth and Gross MarginRevenue growth combined with a relatively stable gross margin indicates continued demand for Sonoma’s products and reasonably consistent product-level economics. If maintained, this combination can support operating leverage and improve the company’s ability to absorb fixed costs over the next several quarters.

Negative Factors

Persistent Operating LossesNegative operating and net margins show that Sonoma’s current revenue base does not yet cover its operating cost structure. Persistent losses weaken internal funding capacity and may require continued financial discipline before growth can produce durable shareholder returns.

Sonoma Pharmaceuticals (O8Z) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 5.27M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -0.9
Beta (1Y): ―
Revenue Growth: ―
EPS Growth: ―
Country: Germany
Employees: 10
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

Sonoma Pharmaceuticals Business Overview & Revenue Model

Company Description

Sonoma Pharmaceuticals, Inc. specializes in the creation and distribution of stabilized hypochlorous acid (HOCl) products. These offerings address a diverse range of medical and health needs, including wound management, veterinary care, ocular hygien...

Sonoma Pharmaceuticals Risk Analysis

Sonoma Pharmaceuticals disclosed 34 risk factors in its most recent earnings report. Sonoma Pharmaceuticals reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Sonoma Pharmaceuticals Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:O8Z against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AMRX	59Neutral	$7.49B	43.24	-326.75%	―	9.28%	4917.17%
DERM	53Neutral	$145.92M	-22.89	-20.23%	―	20.89%	40.71%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AQST	49Neutral	$488.24M	-5.98	243.68%	―	22.56%	5.86%
PRGO	46Neutral	$2.19B	-1.26	-55.97%	7.35%	-4.18%	-2138.82%
ORGO	45Neutral	$98.83M	-0.94	-24.23%	―	6.50%	-613.22%

* Healthcare Sector Average

Performance Comparison

DE:O8Z and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:O8Z	Sonoma Pharmaceuticals, Inc.	2.69	0.00	0.00%
PRGO	Perrigo Company	15.78	-2.98	-15.89%
ORGO	Organogenesis Holdings	0.77	-3.23	-80.80%
AMRX	Amneal Pharma	21.51	10.32	92.14%
AQST	Aquestive Therapeutics, Inc.	3.89	-2.60	-40.06%
DERM	Journey Medical Corporation	5.17	-3.35	-39.32%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Sonoma Pharmaceuticals AI Stock Analysis

Top Page